Literature DB >> 10435394

Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.

D Y Lee1, K U Lee, J S Kwon, I J Jang, M J Cho, S G Shin, J I Woo.   

Abstract

RATIONALE: CNS-active drugs produce specific electroencephalographic changes and the concentration-effect relationship of antipsychotics may be elucidated by adopting electroencephalography (EEG) as an effect measurement tool.
OBJECTIVE: The purpose of the present study was to determine the concentration-effect relationship of risperidone by assessing the EEG effect after oral administrations of single dose risperidone in healthy young males.
METHODS: Nine healthy male volunteers received a 1 mg single oral dose of risperidone according to a placebo controlled crossover design. Plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone were measured by radioimmunoassay. Quantitative EEG parameters were obtained for each of four frequency bands through spectral EEG analysis. The difference in the absolute power in the delta frequency band for the F3 lead between risperidone and placebo was used as a drug effect parameter. For pharmacokinetic-pharmacodynamic modeling, the hypothetical effect compartment kinetically linked to plasma by a first-order process was postulated. All curve fittings were done with the non-linear curve-fitting program NONLIN.
RESULTS: Our results showed that absolute powers in delta and theta frequency bands were higher for risperidone administration than for placebo at all EEG leads, and the maximum effects were detected at about 3 h after administration of the drug. The hysteresis loop was observed in the plot of plasma concentration of risperidone or sum of risperidone and 9-hydroxyrisperidone (Cp) versus EEG effect for each subject. A linear model adequately described the relationship between the effect compartment concentrations (Ce) and EEG effects, and the two limbs of hysteresis in the Cp-effect plot were collapsed in the Ce-effect plot for risperidone or risperidone plus 9-hydroxyrisperidone.
CONCLUSION: The increases of absolute power for delta and theta frequency bands of EEG were induced by single oral administration of risperidone. The linear PK-PD model fit well with the relationship between effect compartment concentrations (Ce) and EEG effects of risperidone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435394     DOI: 10.1007/s002130051003

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

Authors:  Sandra Giménez; Susana Clos; Sergio Romero; Eva Grasa; Adelaida Morte; Manuel J Barbanoj
Journal:  Psychopharmacology (Berl)       Date:  2007-01-05       Impact factor: 4.530

2.  Characterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving rats.

Authors:  W Dimpfel
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

3.  Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

4.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

5.  Itraconazole and domperidone: a placebo-controlled drug interaction study.

Authors:  Tsuneaki Yoshizato; Tsutomu Kotegawa; Hiromitsu Imai; Kimiko Tsutsumi; Junko Imanaga; Tetsuji Ohyama; Kyoichi Ohashi
Journal:  Eur J Clin Pharmacol       Date:  2012-03-15       Impact factor: 2.953

6.  Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers.

Authors:  Jordi Riba; Peter Anderer; Adelaida Morte; Gloria Urbano; Francesc Jané; Bernd Saletu; Manel J Barbanoj
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

7.  Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.

Authors:  T Lehr; A Staab; C Tillmann; E Ø Nielsen; D Trommeshauser; H G Schaefer; C Kloft
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 8.  Electroencephalogram-based pharmacodynamic measures: a review.

Authors:  Michael Bewernitz; Hartmut Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  2012-03       Impact factor: 1.366

9.  Pharmacokinetic-pharmacodynamic model of newly developed dexibuprofen sustained release formulations.

Authors:  Selvadurai Muralidharan
Journal:  ISRN Pharm       Date:  2012-12-06

Review 10.  Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder.

Authors:  Fleur M Howells; Hendrik S Temmingh; Jennifer H Hsieh; Andrea V van Dijen; David S Baldwin; Dan J Stein
Journal:  Transl Psychiatry       Date:  2018-04-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.